465 related articles for article (PubMed ID: 28318914)
1. Systemic and network functions of the microtubule-associated protein tau: Implications for tau-based therapies.
Bakota L; Ussif A; Jeserich G; Brandt R
Mol Cell Neurosci; 2017 Oct; 84():132-141. PubMed ID: 28318914
[TBL] [Abstract][Full Text] [Related]
2. Tau pathology in Alzheimer disease and other tauopathies.
Iqbal K; Alonso Adel C; Chen S; Chohan MO; El-Akkad E; Gong CX; Khatoon S; Li B; Liu F; Rahman A; Tanimukai H; Grundke-Iqbal I
Biochim Biophys Acta; 2005 Jan; 1739(2-3):198-210. PubMed ID: 15615638
[TBL] [Abstract][Full Text] [Related]
3. Sources of extracellular tau and its signaling.
Avila J; Simón D; Díaz-Hernández M; Pintor J; Hernández F
J Alzheimers Dis; 2014; 40 Suppl 1():S7-S15. PubMed ID: 24531154
[TBL] [Abstract][Full Text] [Related]
4. [Neuropathology of tauopathy].
Yoshida M
Brain Nerve; 2013 Dec; 65(12):1445-58. PubMed ID: 24323931
[TBL] [Abstract][Full Text] [Related]
5. Tauopathy: A common mechanism for neurodegeneration and brain aging.
Saha P; Sen N
Mech Ageing Dev; 2019 Mar; 178():72-79. PubMed ID: 30668956
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of tau self-aggregation and neurotoxicity.
Farías G; Cornejo A; Jiménez J; Guzmán L; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):608-14. PubMed ID: 21605046
[TBL] [Abstract][Full Text] [Related]
7. Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration.
Wang JZ; Xia YY; Grundke-Iqbal I; Iqbal K
J Alzheimers Dis; 2013; 33 Suppl 1():S123-39. PubMed ID: 22710920
[TBL] [Abstract][Full Text] [Related]
8. Identification of key amino acids responsible for the distinct aggregation properties of microtubule-associated protein 2 and tau.
Xie C; Soeda Y; Shinzaki Y; In Y; Tomoo K; Ihara Y; Miyasaka T
J Neurochem; 2015 Oct; 135(1):19-26. PubMed ID: 26134402
[TBL] [Abstract][Full Text] [Related]
9. Intrinsically disordered tau protein in Alzheimer's tangles: a coincidence or a rule?
Skrabana R; Skrabanova M; Csokova N; Sevcik J; Novak M
Bratisl Lek Listy; 2006; 107(9-10):354-8. PubMed ID: 17262987
[TBL] [Abstract][Full Text] [Related]
10. Further understanding of tau phosphorylation: implications for therapy.
Medina M; Avila J
Expert Rev Neurother; 2015 Jan; 15(1):115-22. PubMed ID: 25555397
[TBL] [Abstract][Full Text] [Related]
11. Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's disease and other tauopathies.
Reynolds MR; Reyes JF; Fu Y; Bigio EH; Guillozet-Bongaarts AL; Berry RW; Binder LI
J Neurosci; 2006 Oct; 26(42):10636-45. PubMed ID: 17050703
[TBL] [Abstract][Full Text] [Related]
12. Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer's disease.
Salminen A; Ojala J; Kaarniranta K; Hiltunen M; Soininen H
Prog Neurobiol; 2011 Jan; 93(1):99-110. PubMed ID: 21056617
[TBL] [Abstract][Full Text] [Related]
13. Assembly of filamentous tau aggregates in human neuronal cells.
Ko LW; Rush T; Sahara N; Kersh JS; Easson C; Deture M; Lin WL; Connor YD; Yen SH
J Alzheimers Dis; 2004 Dec; 6(6):605-22; discussion 673-81. PubMed ID: 15665401
[TBL] [Abstract][Full Text] [Related]
14. Propagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.
Lewis J; Dickson DW
Acta Neuropathol; 2016 Jan; 131(1):27-48. PubMed ID: 26576562
[TBL] [Abstract][Full Text] [Related]
15. Dephosphorylation Targeting Chimaera (DEPTAC): Targeting Tau Proteins in Tauopathies.
Soumbasis A; Eldeeb MA; Ragheb MA; Zorca CE
Curr Protein Pept Sci; 2022; 23(3):129-132. PubMed ID: 35598241
[TBL] [Abstract][Full Text] [Related]
16. Tau and Axonal Transport Misregulation in Tauopathies.
Combs B; Mueller RL; Morfini G; Brady ST; Kanaan NM
Adv Exp Med Biol; 2019; 1184():81-95. PubMed ID: 32096030
[TBL] [Abstract][Full Text] [Related]
17. Glial contributions to neurodegeneration in tauopathies.
Leyns CEG; Holtzman DM
Mol Neurodegener; 2017 Jun; 12(1):50. PubMed ID: 28662669
[TBL] [Abstract][Full Text] [Related]
18. Tau as a therapeutic target for Alzheimer's disease.
Boutajangout A; Sigurdsson EM; Krishnamurthy PK
Curr Alzheimer Res; 2011 Sep; 8(6):666-77. PubMed ID: 21679154
[TBL] [Abstract][Full Text] [Related]
19. A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model.
Zhang B; Yao Y; Cornec AS; Oukoloff K; James MJ; Koivula P; Trojanowski JQ; Smith AB; Lee VM; Ballatore C; Brunden KR
Mol Neurodegener; 2018 Nov; 13(1):59. PubMed ID: 30404654
[TBL] [Abstract][Full Text] [Related]
20. Tau, tau kinases, and tauopathies: An updated overview.
Montalto G; Ricciarelli R
Biofactors; 2023; 49(3):502-511. PubMed ID: 36688478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
